January 24, 2015
A 40% dose of intradermal inactivated polio vaccine achieved noninferior antibody responses in HIV patients compared with a full dose administered intramuscularly, according to the results of a randomized controlled trial.
“We conducted this study in HIV-infected adults because they have suboptimal responses to many vaccines even with well-controlled HIV infection, a finding felt to be related to chronic immune activation,” the researchers wrote in the Journal of Infectious Diseases. “Consequently, we felt that this population could function as a surrogate for populations in the developing world with suboptimal vaccine responses.”
The researchers evaluated the inactivated polio vaccine (IPV) in 231 adult HIV patients with well-controlled disease (viral load<400 copies/mL) who were being treated at the Eastern Virginia Medical School HIV clinic in Norfolk, Va., between Sept. 7, 2012 and July 8, 2013.